1. What do Cochrane systematic reviews say about the use of cannabinoids in clinical practice?
- Author
-
Daniela Vianna Pachito, Carolina de Oliveira Cruz Latorraca, Rafael Leite Pacheco, Ana Luiza Cabrera Martimbianco, and Rachel Riera
- Subjects
medicine.medical_specialty ,Evidence-based medicine ,Evidence-based practice ,Fibromyalgia ,Nausea ,Vomiting ,Population ,MEDLINE ,lcsh:Medicine ,HIV Infections ,03 medical and health sciences ,Therapeutic approach ,0302 clinical medicine ,parasitic diseases ,medicine ,Humans ,030212 general & internal medicine ,Intensive care medicine ,education ,Cannabis ,education.field_of_study ,Epilepsy ,Evidence-Based Medicine ,biology ,business.industry ,Cannabinoids ,lcsh:R ,General Medicine ,biology.organism_classification ,Systematic review ,Schizophrenia ,Dementia ,medicine.symptom ,business ,030217 neurology & neurosurgery ,Systematic Reviews as Topic ,Tourette Syndrome ,Review [publication type] - Abstract
BACKGROUND: The therapeutic effects of cannabinoid compounds have been the center of many investigations. This study provides a synthesis on all Cochrane systematic reviews (SRs) that assessed the use of cannabinoids as a therapeutic approach. DESIGN AND SETTING: Review of SRs, conducted in the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (UNIFESP). METHODS: A broad search was conducted in the Cochrane Database of Systematic Reviews to retrieve any Cochrane SRs that assessed the efficacy and safety of cannabinoids as a therapeutic approach. The results and key characteristics of all reviews included were summarized and discussed. RESULTS: Eight SRs were included. They assessed the use of cannabinoids for the following types of conditions: neurological (two SRs), psychiatric (two SRs), rheumatological (one SR), infectious (one SR) and oncological (two SRs). There was moderate-quality evidence showing that the use of cannabinoids reduced nausea and vomiting among adults, compared with placebo. Additionally, there was moderate-quality evidence showing that there was no difference between cannabinoids and prochlorperazine regarding the number of participants who reported vomiting, in this same population. CONCLUSIONS: This review identified eight Cochrane systematic reviews that provided evidence of unknown to moderate quality regarding the use of cannabinoids as a therapeutic intervention. Further studies are still imperative for solid conclusions to be reached regarding practical recommendations.
- Published
- 2018